<DOC>
	<DOCNO>NCT01730014</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerability , pharmacokinetics ( exposure trial drug body ) pharmacodynamics ( effect investigate drug body ) subcutaneous NNC0148-0000-0287 ( insulin 287 ) healthy subject subject type 1 diabetes</brief_summary>
	<brief_title>A Trial Investigating Safety , Tolerability , Distribution Activity Body NNC0148-0000-0287 Injected Under Skin Healthy Subjects Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>TRIAL PART 1 ( HEALTHY SUBJECTS ) : Healthy male subject Age 1855 year ( inclusive ) Body mass index 18.028.0 kg/m^2 ( inclusive ) TRIAL PART 2 ( SUBJECTS WITH TYPE 1 DIABETES ) : Healthy male subject ( exception condition associate diabetes mellitus ) Age 1864 year ( inclusive ) Body mass index 18.028.0 kg/m^2 ( incl . ) Type 1 diabetes mellitus ( diagnose clinically ) treat multiple daily insulin injection 12 month HbA1C ( glycosylated haemoglobin ) equal 8.5 % Current daily basal insulin requirement equal 0.2 equal 0.8 ( I ) U/kg/day current total daily insulin treatment 1.2 ( I ) U/kg/day Fasting Cpeptide 0.3 nmol/L The receipt investigational medicinal product within last 3 month prior start trial ( screen ) Significant blood loss ( due donation , surgery trauma ) 500 mL within 3 month prior start trial ( screen ) participate trial involve blood sample within last 2 month start trial ( screen ) Use prescription ( see specification Trial Part 2 ) nonprescription medication , include herbal product nonroutine vitamin , within last 2 week start trial ( screen ) interfere pharmacokinetics insulin 287 , judge investigator agreement sponsor . Routine vitamin occasional use judge investigator agreement sponsor . Routine vitamin occasional use paracetamol permit 48 hour prior dose History alcoholism drug abuse ( within last 2 year ) , positive result alcohol drug screen test Currently smoke 1 cigarette per day ( equivalent tobacco product ) smoke 1 cigarette less per day consider able refrain smoking refrain use type nicotine product ( e.g . chew tobacco , nicotine gum ) inhouse period Habitual excessive consumption methylxanthinecontaining ( theophylline , caffeine theobromine ) beverages food ( coffee , tea , soft drink red bull , cola , chocolate ) judge investigator Excessive consumption diet deviate normal diet judge investigator Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation trial Vulnerable subject ( e.g . person keep detention ) Subject investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct trial ADDITIONAL KEY EXCLUSION CRITERIA TRIAL PART 2 ( subject type 1 diabetes ) : Current treatment statin , systemic ( oral , intravenous inhale ) corticosteroid , monoamine oxidase ( MAO ) inhibitor , nonselective betablockers , thyroid hormone , growth hormone drug , may interfere glucose metabolism Increased risk thrombosis , e.g . subject history deep leg vein thrombosis family history deep leg vein thrombosis , judge investigator Recurrent severe hypoglycaemia ( 1 severe hypoglycaemic event last 12 month ) hypoglycaemic unawareness judge Investigator hospitalisation diabetic ketoacidosis past 6 month start trial ( screen ) Cardiac problem define : decompensated heart failure ( New York Heart Association ( NYHA ) class III IV ) time , acute myocardial infarction time , angina pectoris within last 12 month start trial ( screen ) Proliferative retinopathy maculopathy and/or severe neuropathy , particular autonomic neuropathy , judge investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>